Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?

Editorial

G M Clark. J Natl Cancer Inst. 1998.

. 1998 Sep 16;90(18):1320-1.

doi: 10.1093/jnci/90.18.1320.

No abstract available

Comment on

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET. Thor AD, et al. J Natl Cancer Inst. 1998 Sep 16;90(18):1346-60. doi: 10.1093/jnci/90.18.1346. J Natl Cancer Inst. 1998. PMID: 9747866 Clinical Trial.
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.
Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N. Paik S, et al. J Natl Cancer Inst. 1998 Sep 16;90(18):1361-70. doi: 10.1093/jnci/90.18.1361. J Natl Cancer Inst. 1998. PMID: 9747867